Bioxytran (BIXT) EBIT Growth (3y) (2013 - 2026)
Bioxytran (BIXT) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 69.02% |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 24.14% |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 44.54% |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 44.34% |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | -28.30% |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 81.27% |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | -18.82% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 14.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.09% |
| Dec 31, 2025 | 17.83% |
| Sep 30, 2025 | -232.83% |
| Jun 30, 2025 | 25.28% |
| Mar 31, 2025 | 14.32% |
| Dec 31, 2024 | 19.50% |
| Sep 30, 2024 | 14.15% |
| Jun 30, 2024 | 16.39% |
| Mar 31, 2024 | 22.73% |
| Dec 31, 2023 | -9.05% |
| Sep 30, 2023 | -104.96% |
| Jun 30, 2023 | -111.43% |
| Mar 31, 2023 | -41.28% |
| Dec 31, 2022 | -29.87% |
| Sep 30, 2022 | 26.34% |
| Jun 30, 2022 | -71.50% |
| Mar 31, 2022 | -84.88% |
| Dec 31, 2021 | -77.76% |
| Sep 30, 2021 | -125.82% |
| Jun 30, 2021 | -1,459.15% |